Cytologic sampling is the mainstay of diagnosing advanced lung cancer. Moreover, to select patients for personalized first-line or second-line treatment, epidermal growth factor receptor (EGFR) mutations and anaplastic lymphoma kinase (ALK) and c-ros oncogene 1 (ROS1) rearrangements are tested on cytologic preparations. Commercially available fluorescence in situ hybridization (FISH) and immunocytochemistry (ICC) assays have primarily been used for the identification of cells harboring ALK or ROS1 gene fusions on histologic rather than cytologic preparations. However, it is now recognized that FISH and ICC also can be applied on cytologic samples provided the cytopathologist is aware that FISH and ICC results are not always concordant and that the performance of ICC largely depends on antibody clones, signal detection systems, and scoring systems. Notably, the routine clinical use of FISH and ICC may be replaced by emerging next-generation sequencing and digital, color-coded barcode technologies, which have the advantage of simultaneously evaluating ALK, ROS1, and EGFR alterations in a single analysis. Although their use in clinical cytologic practice remains to be fully established, it is conceivable that this technology will replace both FISH and ICC analyses in future diagnostic algorithms. Here, the authors review studies devoted to testing ALK and ROS1 on cytology specimens in an attempt to provide an update for the cytopathologist regarding current and evolving practice.
INTRODUCTION
Nonsmall cell lung cancer (NSCLC), which accounts for 80% of all lung cancers, is usually diagnosed at an inoperable stage. 1 In these patients, interventional radiologic and/or image-guided endoscopic techniques yield small tumor samples. 1 Although formalin-fixed, paraffin-embedded (FFPE) histologic specimens are increasingly being received in large cancer centers, 2 cytologic samples are still the only font of diagnostic material available in most laboratories. [3] [4] [5] Cytodiagnostics may entail rapid on-site evaluation (ROSE) to verify the presence of cancer cells and to readily submit samples for biomarker testing. 6 The latter procedure involves "companion diagnostic" tests to identify distinct molecular subtypes of adenocarcinoma that can be treated using personalized therapies, such as those featuring epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma receptor tyrosine kinase (ALK) gene rearrangements. 7 Because EGFR and ALK tyrosine kinase inhibitors also have been approved by the US Food and Drug Administration (FDA) in the first-line treatment setting, potentially responsive tumors it is noteworthy that, with respect to established technologies, such as fluorescence in situ hybridization (FISH) and immunocytochemistry (ICC), the emerging nextgeneration sequencing (NGS) and digital, color-coded barcode technologies (nCounter; NanoString Technologies, Seattle, Washington) have the advantage of evaluating ALK, ROS1, and EGFR alterations in a single analysis. Although their use in clinical cytologic practice remains to be established, these technologies may play more relevant roles in future diagnostic algorithms. Given the large body of data that has accumulated in recent years on gene fusion testing, it seems that the time is now ripe to provide an update for practicing cytopathologists about issues related to current and evolving practice, particularly the various test requirements of the different types of cytologic specimens (aspirate, exfoliative, and effusions) and cytopreparations (cell block, smears, and monolayer slides [ThinPrep; Hologic, Inc, Danbury, Connecticut]). 11, 12 ALK REARRANGEMENT DETECTION TECHNIQUES ALK gene rearrangements are actionable driver alterations occurring in a small (range, 3%-5%) but significant subset of NSCLCs, specifically adenocarcinomas usually occurring in younger patients and in light smokers or neversmokers. 7, 13 Compared with fusion-negative ALK lung adenocarcinomas, tumors that harbor a fusion gene are characterized by extracellular mucin, a cribriform pattern, and signet ring cells. 14 The most common ALK rearrangement is caused by a small intrachromosomal inversion within the short arm of chromosome 2 that leads to the oncogenic echinoderm microtubule-associated protein-like 4 gene (EML4)-ALK fusion transcript. 13 Although the breakpoint of ALK is constant at exon 20, breakpoints in the amino terminal of EML4 vary from exon 2 to exon 20 and lead to more than 21 different EML4-ALK gene fusions. 7 Kinesin family member 5B, the tropomyosin receptor kinase (TRK)-fused gene, and kinesin light chain 1 are more rare fusion partners of ALK.
14 Treatment with ALK inhibitors is appropriate in patients who harbor ALK gene fusions irrespective of the gene fusion partner. 7 The tyrosine kinase inhibitors crizotinib, ceritinib, and alectinib have been approved by the FDA for the treatment of patients harboring ALK rearrangements and are characterized by high (approximately 60%-70%) objective response rates and by a longer progression-free survival compared with conventional chemotherapy. 15 In clinical trials of the drug crizotinib, the companion diagnostic test was the FISH assay performed using "breakapart" probes (ALK FISH Break-Apart Kit; Vysis, Abbott Molecular, Abbott Park, Illinois). 15 This test is FDAapproved and consists of red (3 0 end) and green (5 0 end) probes that flank the highly conserved translocation breakpoint within the ALK gene. Normal cells feature yellow, intact signals; whereas neoplastic cells harboring ALK rearrangements exhibit split red and green signals (Fig. 1) . 7 A case is interpreted as ALK-positive by FISH when 15% or more tumor cell nuclei exhibit distinctly separated green and red signals or isolated red signals. 7 The thresholds for positive ALK status may not differ significantly between cytologic and histologic preparations. 16 ICC is a cost-effective surrogate for the predictive ALK test. 17 Recently, the Ventana ALK (D5F3) immunohistochemistry (IHC) companion diagnostic (CDx) assay (Medical Systems Inc, Tucson, Arizona), which was used in the clinical trials of ceritinib and alectinib, received FDA approval. 18 However, both FISH and ICC assays have been FDA approved only for "routinely processed, paraffin-embedded specimens that have been fixed in neutral-buffered formalin." 12 Thus, current ALK testing guidelines recommend the preparation of an FFPE cell block from the cytology sample, which can then be processed and sectioned like a tissue sample for screening by ICC, eventually followed by a confirmatory FISH assay in those cases with equivocal immunostaining. 19, 20 However, because tumor sampling by minimally invasive cytologic procedures does not always provide sufficient material for additional cell block preparation, conventional smears also should be used for ALK FISH and/or ICC tests, provided that an in-house validation procedure is established. 7 As an alternative to the FISH and ICC in situ techniques, RNA can be extracted from cytologic samples and processed by the more sensitive reverse transcriptasepolymerase chain reaction (RT-PCR) procedure. 21 However, this approach is limited by the requirement for highquality RNA and by the risk that rare fusion variants may not be captured. 7 It was recently demonstrated that highthroughput, transcriptome-based procedures, namely, NGS and the nCounter methodology (NanoString Technologies), are robust alternatives to FISH and IHC testing; moreover, they enable multiplex screening of large numbers of actionable gene fusions. 22 The above-reported ALK rearrangement detection techniques are discussed below in terms of cytologic specimen type and source.
ALK Testing on Cell Blocks
Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA), as an alternative to mediastinoscopy, is a minimally invasive procedure that integrates real-time evaluation during bronchoscopy and sampling of mediastinal and pulmonary hilar lymph nodes and parenchymal masses in patients with advanced NSCLC for morphologic diagnosis, staging, and molecular analysis. 23 Several studies, which are summarized in Table 1 , have demonstrated that cell blocks obtained by EBUS-TBNA can be reliably used for ALK FISH testing; indeed, informative results were obtained in greater than 90% of cases, [24] [25] [26] [27] [28] and the rearrangement detection rate was similar (3.9%) to that of surgical specimens (3.4%). 24 Malignant pleural effusions (MPEs) may occur as the initial presenting manifestation in patients with advanced lung cancer, especially adenocarcinoma, and thus represent an easily accessible source of malignant cells for the detection of ALK rearrangements when tissue is not available. 50 Fresh, unfixed pleural fluid ensures optimal quality RNA for RT-PCR assays. 51 It can also be centrifuged, and the cellular components obtained can used for the preparation of FFPE cell blocks. 50 Compared with pleural fluid preparations, MPE cell blocks enable the cytologist to correlate the molecular findings with malignant cell content, and they are also suitable for use with the Ventana ALK (D5F3) CDx assay. A recent series of studies indicated that the latter assay is the best method for ALK detection in MPE cell blocks. Indeed, the results obtained were highly concordant with matched tissue samples, 29 the assay was more sensitive than the FISH procedure (Table 1) , 30 and it was informative even when FISH enumeration could not be performed because of insufficient numbers (<50) of For each study, the type of specimen and preparation, the testing modality, the number of tested and adequate cases, and the prevalence of ALK rearrangements are reported. Sensitivity and specificity with respect to the gold standard are reported where available.
b These were only patients who had adenocarcinoma or nonsmall cell lung cancer, not otherwise specified, harboring wild-type EGFR and K-RAS.
c
The number of cases processed by FC and DS were not reported.
tumor cells. 31 In summary, based on the evidence now available, both FISH and ICC assays can readily be carried out on cell blocks.
ALK FISH Testing on Cytologic Slides
Although the use of cell block sections for ALK testing is still recommended over smears, a draft document circulated for open comment preliminary to the upcoming College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology revised recommendations acknowledges the use of conventional cytologic preparations for ALK FISH. 52 Indeed, recent evidence indicates that ALK FISH testing using direct smears, which circumvents nuclear truncation and ensures better DNA preservation than FFPE samples, is highly sensitive. 53 In a cytology study of 32 lung adenocarcinomas analyzed for ALK rearrangements using matched FISH and smears, concordance was obtained in 31 of 32 cases (97%). In the 1 discordant case, an ALK rearrangement was detected on the direct smear, and RT-PCR confirmed the rearrangement. 32 Accordingly, FISH performed using cytologic smears provides information about ALK status in most cases, 33, 34 and FISH positivity on cytology reliably predicts tumor response. 35 Indeed, of the 9 ALK FISH-positive patients who received crizotinib treatment, 8 (88.9%) exhibited tumor regression. 35 FISH analysis can also be performed on monolayered (ThinPrep) cytologic slides. 36, 54 In fact, it was nearly always concordant (152 of 154 cases) with the evaluation of matched cell blocks using ultrasensitive D5F3 ALK-IHC. 36 Thus, ThinPrep-FISH can be used for testing when the cell block is paucicellular. The preanalytic steps, ie, before hybridization, affect the interpretation of probe signals. 53 In a recent study of 91 smears, mostly represented by Cytofix-processed (BD Biosciences, Franklin Lakes, New Jersey) and Papanicolaou-stained slides, 24 (26%) could not be evaluated because of artifacts or cell overlap. FISH also failed in 3 of 17 cases(17%) because of cell detachment when carried out on the Diff-Quikstained smear used for ROSE. Thus, after ROSE, an additional fixation using Carnoy solution (methanol-acetic acid, 3:1) for 20 minutes must be performed. 37 A preliminary de-staining step should not be performed for archival slides, because a green background fluorescence can interfere with the visualization of ALK signals. 38, 39 FISH also is feasible on the same slide used for immunostaining (ie, thyroid transcription factor 1 [TTF1]) as long as autofluorescent diaminobenzidine is not used as chromogen. 55 In addition, ALK FISH analysis does not interfere with DNA extraction for subsequent PCR-based EGFR testing. 56, 57 All of the data reported above suggest that cytologic slides be used for ALK rearrangement analysis by FISH when cell blocks are not sufficiently cellular.
Limits of ALK FISH
The use of FISH as a screening tool for all patients with NSCLC is limited by the cumbersome nature of the method, the long turn-around time, and its high costs. 55 Moreover, not all laboratories have access to the advanced equipment required for this procedure. Morphology cannot be appreciated after hybridization; thus, relocation software combined with an automated stage must be used to relocate the neoplastic cells, because it is almost impossible to relocate them manually. 58 61 In fact, whereas FISH-positive cells are scattered throughout the tumor, the aberrant ALK protein is usually expressed in all cells. 61 Indeed, FISH has inherent limitations for testing ALK gene fusions, because the intrachromosomal inversion event involves only a small part of the short arm of chromosome 2. Therefore, it may be difficult to identify the narrow separation between the red and the green signals because of the proximity of probes. 55 Moreover, the performance of FISH depends on several preanalytic factors, namely, fixation time and fixative type. 53, 63 Consequently, current expert opinion holds that an ALKpositive cell rate close to 15% is "borderline" and requires additional evaluation. 64 
ALK Immunocytochemistry
A more reasonable alternative to FISH is to screen for ALK rearrangements with ICC. 7 In fact, this procedure is faster, significantly less expensive, and more informative than FISH even on paucicellular smears in which rare positive cells or cell groups among a majority of non-neoplastic reactive cells are easily missed by FISH. 65 The normal ALK protein is undetectable by IHC, whereas the abnormal protein, containing the activated ALK tyrosine kinase moiety, is detectable by ultrasensitive antibodies such as clones 5A4 (Novocastra, Leica Biosystems; Newcastle Upon Tyne, UK) and D5F3 (Cell Signaling Technology, Danvers, Massachusetts). 12, 19 Clone 5A4 associated with the Novolink (Leica Biosystems) ICC detection system has a wide dynamic range of staining and 4 scores (0, 11, 21, and 31). 66 This scoring system is based on the evaluation of staining intensity rather than on the percentage of positive cells. 5A4 ICC scores of 0 and 31 are nearly 100% concordant with FISH status. 19 Conversely, 5A4 ICC scores of 11 and 21 must be verified in a FISH assay. Indeed, up to 80% of cases with a 5A4 score of 11 and a significant subset (20%) of with a 5A4 score of 21 were not confirmed by FISH and thus were considered falsepositive 5A4 ALK IHC resultsd. 19 In addition, intensity scores of 11 and 21 are poorly reproducible. However, the microscope objective lens may be a useful method with which to establish staining intensity in a more objective fashion. In fact, 31 intensity is readily visible with a 32 or 34 lens, moderate staining intensity (21) is visible with a 310 or 320 objective lens, and weak low-intensity signals (11) can only be identified with a 340 objective lens. 67 The D5F3 clone is marketed by Ventana Medical Systems as part of the ALK CDx assay, as mentioned above. 18 This "real-time ICC" requires as little as 4.5 hours to identify gene rearrangement carriers who can benefit from anti-ALK treatment. 18 This test features a complex detection system that includes a tyramide-based amplification phase in addition to the polymeric step (OptiView; Ventana Medical Systems). Thanks to these sequential layers, the signal difference is increased between the specific immunoreaction and the background signal; thus, equivocal results are reduced or eliminated. 18, 61 Consequently, a dichotomous scoring system (positive or negative ALK status) is used to evaluate the staining results. Only cases that exhibit a strong, granular cytoplasmic signal are scored positive regardless of the percentage of stained cells (Fig. 3) . 18 In summary, when interpreting results, the cytopathologist should be aware of the differences in antibody clones, signal detection systems, and scoring systems adopted.
ALK Immunocytochemistry on Smears
ICC on smears and/or cytospin slides is challenging, because antibodies are usually validated for FFPE specimens, and each antibody must be revalidated to ensure that assays consistently achieve the expected results. 68, 69 For example, to validate the mouse monoclonal ALK antibody (5A4) on smears, Savic et al analyzed 41 cytologic slides with known ALK FISH status, including 15 with ALK rearrangements. 16 Only 2 of 41 cases were FISH/ ICC-discordant, 1 of which was a carcinoma with weak staining intensity (11) that was negative on a FISH assay. Alcohol fixation of histologic samples was considered problematic for histology-based ALK ICC, because it reduced tissue staining intensity, 70 whereas alcohol fixation did not appear to adversely affect ALK ICC on smears (Fig. 3) .
40,41
The cell-transfer technique is another method with which to obtain cellular material from direct smears for ALK staining. 42 Commercially available control material, such as cell lines and xenografts harboring ALK rearrangements and featuring intense immunostaining, can serve as positive controls to ensure the reliability of reagents and protocols.
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ROS1
A small subset (1%-2%) of patients affected by NSCLC harbor ROS1 rearrangements without other oncogenic mutations or rearrangements. 72 These patients are predominantly young women and never-smokers. 73 In addition to the morphologic features of fusion-positive ALK lung adenocarcinomas (extracellular mucin, cribriform pattern, and signet ring cells), 14 ROS1-positive tumors exhibit hepatoid cytology (abundant eosinophilic cytoplasm, round and relatively monomorphic nuclei, and prominent nucleoli). 74 Crizotinib, which induced an impressive dramatic objective clinical response in 72% of ROS1-positive patients with advanced-stage NSCLC, 9 recently was approved by the FDA also for ROS1-rearranged adenocarcinomas. In the clinical trials with crizotinib, ROS1-positive patients were identified by break-apart FISH; consequently, the FDA considers this method to be the "gold standard" procedure with which to determine ROS1 positivity. 9 Evaluation criteria are the same as those for ALK, because there are 2 positive ROS1 rearrangement patterns: the "classic" (3 0 and 5 0 split pattern) and the "atypical" patterns (with a single 3 0 signal) (Fig. 2) . 75 Similar to ALK, an automated software system is an aid to scoring results. Only 2 studies have performed ROS1 FISH on cytologic preparations (Table 2) . 27, 38, 48 One of those studies used FFPE cell blocks, 27 and the other used smears. 38 The latter study identified the ROS1 rearrangement in Figure 3 . Immunocytochemistry with the D5F3 assay is observed (a-d) on cytologic samples of lung adenocarcinoma on cell block and (e-h) and Papanicolaou-stained smears. On both cytologic preparations, neoplastic cells exhibited strong, granular, cytoplasmic signal, indicating aberrant anaplastic lymphoma kinase protein expression generated by gene fusion.
2 smears, and this result was confirmed on matched FFPE preparations. 38 Results from recent studies carried out on NSCLC histologic samples using the rabbit monoclonal antibody D4D6 (Cell Signaling Technology) correlated well with FISH results. [76] [77] [78] Therefore, IHC staining using the D4D6 antibody also can be considered a valid screening tool with which to detect ROS1-positive tumors. However, clone D4D6 may yield false-positive results. Indeed, nonneoplastic hyperplastic type II pneumocytes and alveolar macrophages occasionally may be slightly reactive. 76 Therefore, only tumors with a moderate-to-strong intensity signal (scores of 21 or 31) in greater than 50% of tumor cells should be considered positive. 17, 79 Moreover, D4D6 antibody dilution, antigen retrieval methods, amplification, and scoring systems are poorly standardized. 75 In an analogy to histologic tissue, FFPE cell-block sections can be stained with D4D6. It is noteworthy that the D4D6 clone also performs well on smears, and the same conventional Papanicolaou-stained slide can be stained first by ROS1 antibody and then, in case of a positive signal, can be used to confirm FISH. 75 
ALK AND ROS1 RT-PCR
Another method for detecting gene fusion is RT-PCR with specific fusion primers. This method can reliably be carried out when RNA is extracted from fresh pleural fluid. Fresh, unfixed cells may readily be processed for immediate nucleic acid extraction to obtain high-integrity RNA. 50 RT-PCR may not always be informative when RNA is extracted from FFPE cell blocks, especially at reference laboratories that receive samples from centers in which fixation and cytopreparation are poorly standardized. 43 ALK
RT-PCR can also be applied on RNA directly extracted from the brush head 44 or from fresh or archival cytologic slides. 45 Mitiushkina et al 46 and, more recently, Oktay and colleagues 47 obtained a 100% rate of success with archival cytologic slides. The latter study was conducted with as few as 50 cells obtained from a cancer cell-rich microscopic field, thereby leaving sufficient diagnostic material for the archives. 47 The pros and cons of the different types of cytologic preparations used for molecular assays are described extensively elsewhere. 10, 11, 23, 50, 57, 63 Current guidelines do not recommend RT-PCR as an alternative to FISH or IHC for the selection of patients for ALK and ROS1 inhibitor therapy. 7 RT-PCR assays, even when multiplexed, cover only the most common fusion variants. For example, the assay used by Wang et al 80 Abbreviations: BB, bronchial brushing; C, cytospin; CB, cell block; DS, direct smear; EBUS-TBNA, Endobronchial ultrasound transbronchial aspiration; FNA, fine-needle aspiration; ICC, immunocytochemistry; MPE, malignant pleural effusion; NGS, Next generation sequencing; ROS1, c-ros oncogene 1. a For each study, the specimen type and preparation, the testing modality, the number of tested and adequate cases, and the prevalence of ROS1 rearrangement are reported. Where possible, data evaluation of test performance relative to the gold standard is also reported. b This series of 11 cytologic samples had been enriched with 9 fluorescence in situ hybridization-positive samples (ALK, n 5 8; ROS1, n 5 1).
NHS of ALK and ROS1
The Guidelines Panel of the National Comprehensive Cancer Network recently endorsed NGS as a primary diagnostic tool. 83 This recently developed technology allows the simultaneous assessment of multiple mutations in multiple genes in multiple patient samples. NGS gene panels are more effective than single-biomarker detection, particularly in the case of cytology samples, in which the amount of material available is often limited. Until recently, NGS was available only in large cancer centers. However, thanks to the advent of smaller gene panels 84, 85 and commercially available NGS assays with automated bioinformatics pipelines, 86 NGS now also can be conducted in smaller pathology departments with limited resources and bioinformatics expertise. In addition to point mutations, deletions, insertions, and copy number variations, NGS simultaneously detects known and unknown ALK and ROS1 rearrangements. 87 The most widely used NGS benchtop sequencers are the Illumina series (San Diego, California) and the IonTorrent series (Thermo Fisher Scientific, South San Francisco, California), which differ in DNA input requirements, run time, and cost per sample. Although Illumina sequencers are more versatile and scalable because they can process both narrow and comprehensive gene panels, they require a larger nucleic acid input and have a longer sequencing time. Thus, most cytology-based studies used IonTorrent sequencing platforms, which ensure consistent results even with less than 10 ng of DNA input, and are the platforms of choice with which to run small gene panels on samples that have a low DNA or RNA yield. 10 Figure 4 indicates that, regardless of the specific features of any single type of platform, the gene fusion detection NGS workflow consists of 4 sequential phases: generation of a short-fragment combinational DNA library, single-fragment clonal amplification, massive parallel sequencing, and sequencing data analysis with the informatics pipeline. 88 To date, most studies conducted using NGS on cytologic preparations have been devoted to somatic mutations, whereas the feasibility of this approach for the detection of ALK and ROS1 rearrangements has not yet been established. 88 By using the Ion AmpliSeq RNA In a study by Yamamoto and colleagues, RNA was extracted from cytologic specimens derived from fluid aspiration, namely, cerebrospinal fluid, pleural effusion, abdominal fluid, and pericardial effusion; and ALK fusion genes were detected in 2.4% of 365 patients. 51 This finding supports the view that detecting the abundance of the ALK protein may be more clinically relevant than identifying a variation at the ALK genomic locus.
In conclusion, all of the studies reported above support the view that NGS has the potential to improve the identification of ALK and ROS1 fusion genes. Thus, it is foreseeable that, in the very near future, NGS will become the standard initial test for the molecular genotyping of patients with advanced cancers. 
ALK ON NCOUNTER
The nCounter system (NanoString Technologies) is a relatively inexpensive and fast hybridization method with which to detect gene fusions on a minute amount of RNA (Fig. 5) . 93 In brief, each target of interest is detected by a unique pair of capture and reporter probes whose sequences are adjacent and complementary to a particular messenger RNA. The capture probe is biotinylated, whereas the reporter probe is linked to a digital color barcode. Each pair of probes is hybridized in a multiplex reaction with the targeted messenger RNA. 94 Preliminary data suggest that nCounter analysis is feasible on routine cytologic smears. 93 To date, nCounter-generated ALK and ROS1 data have been obtained only on histologic samples. Although the failure rate for the nCounter RNA gene fusion assay is not negligible (20%), 22 nCounter analysis is highly concordant with FISH and IHC and thus is very specific. [93] [94] [95] [96] For example, Reguart and coworkers analyzed 98 samples from patients with advanced NSCLC using nCounter and identified 32 (32.7%) ALK fusion-positive samples and 21 (21.4%) ROS1 fusion-positive samples. 94 There was a high degree of concordance between nCounter results and the results from ALK immunostaining, FISH, and RT-PCR, which were 98.5%, 87%, and 85.7%, respectively. Similar concordance rates were reported for ROS1 (IHC, 87.2%; FISH, 85.9%). 94 These data were confirmed by Lira et al 95, 97 and by Sunami and colleagues 96 In another study, nCounter analysis did not reveal any ALK or ROS1 alterations in pure squamous cell carcinoma without an adenocarcinoma component. 98 Finally, Fang and coworkers demonstrated that patientderived xenografts also can be used to detect ALK rearrangements and to assess crizotinib responsiveness using nCounter technololgy. 99 
CONCLUSIONS
Established technologies like FISH and ICC can easily be applied to cell blocks and, after preliminary validation, even to direct smears. 100 However, when ordering an ALK test and interpreting the results, the cytopathologist should be aware of the thresholds for a positive FISH or ICC ALK status. Indeed, caution should be exercised when the number of FISH-positive cells only slightly exceeds the 15% cutoff or when the 5A4 clone yields an intermediate score (11 or 21) . This is particularly the case in young and nonsmoking patients and in those who have tumors with specific cytomorphologic features. In such patients, a combined approach that includes RT-PCR and emerging technologies is required. In this context, the teaching of cytopathology should include basic training on the aim, scope, and methodology of actionable gene fusion detection on cytologic preparations. In summary, NGS and nCounter testing of RNA extracted from cytologic samples is a promising and fascinating field of investigation that aims at identifying all ALK-negative and ROS1-positive patients.
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